Proficio Capital Partners LLC boosted its position in Sanofi (NYSE:SNY) by 15.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,910 shares of the company’s stock after buying an additional 645 shares during the period. Proficio Capital Partners LLC’s holdings in Sanofi were worth $233,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently modified their holdings of the company. Harbour Capital Advisors LLC bought a new stake in shares of Sanofi during the first quarter worth about $113,000. Eagle Ridge Investment Management bought a new stake in shares of Sanofi during the second quarter worth about $160,000. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the period. Huntington National Bank raised its stake in shares of Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock worth $202,000 after buying an additional 147 shares during the period. Finally, Boyd Watterson Asset Management LLC OH bought a new stake in shares of Sanofi during the first quarter worth about $213,000. Hedge funds and other institutional investors own 9.90% of the company’s stock.
Sanofi (SNY) opened at 48.19 on Friday. The stock has a 50 day moving average of $47.84 and a 200 day moving average of $46.41. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24. The company has a market capitalization of $121.03 billion, a PE ratio of 11.43 and a beta of 0.88.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the consensus estimate of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s revenue was down 2.3% compared to the same quarter last year. On average, equities research analysts predict that Sanofi will post $3.26 EPS for the current year.
A number of equities research analysts have recently issued reports on SNY shares. Zacks Investment Research lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Berenberg Bank lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. BidaskClub lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Finally, Argus upped their target price on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $54.00.
About Sanofi
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
